• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[偏倚风险2工具的应用]

[Application of the Risk of Bias 2 Tool].

作者信息

Lee Ling-Ling

机构信息

PhD, RN, Associate Professor, Department of Nursing, College of Nursing, Tzu Chi University of Science and Technology, Taiwan, ROC.

出版信息

Hu Li Za Zhi. 2021 Apr;68(2):85-91. doi: 10.6224/JN.202104_68(2).11.

DOI:10.6224/JN.202104_68(2).11
PMID:33792022
Abstract

The Cochrane risk of bias (RoB) tool is used widely in systematic review studies and evidence-based healthcare. However, how this tool is used and how domains and signaling questions are interpreted may vary significantly across studies. This article was written to illustrate the limitations of the Risk of Bias tool version 1, which have been addressed in the new version of this tool, Risk of Bias version 2 (RoB 2). In addition to introducing the five domains (including risk of bias due to the randomization process, deviations from the intended interventions, missing outcome data, measurement of the outcome, and selection of reported results) and the assessment of overall bias risk, the procedure of using the RoB 2 tool to assess randomized controlled trials when conducting a systematic review study and evidence-based practice is also introduced. The structure of pre-, during-, and post-assessment is used in this article to describe clearly the procedure of bias assessment. An overall introduction to the relevant resources related to RoB 2 (such as guidance, software, and websites) is also addressed, to further enhance the familiarity with RoB 2 of nursing staffs and systematic review researchers and to increase their ability to use this tool effectively.

摘要

Cochrane偏倚风险(RoB)工具在系统评价研究和循证医疗中被广泛使用。然而,该工具的使用方式以及各领域和信号问题的解释在不同研究中可能存在显著差异。本文旨在阐述偏倚风险工具第1版的局限性,这些局限性在该工具的新版本——偏倚风险第2版(RoB 2)中已得到解决。除了介绍五个领域(包括随机化过程导致的偏倚风险、与预期干预的偏离、结局数据缺失、结局测量以及报告结果的选择)和整体偏倚风险评估外,还介绍了在进行系统评价研究和循证实践时使用RoB 2工具评估随机对照试验的程序。本文采用评估前、评估期间和评估后的结构来清晰描述偏倚评估程序。此外,还对与RoB 2相关的资源(如指南、软件和网站)进行了全面介绍,以进一步提高护理人员和系统评价研究人员对RoB 2的熟悉程度,并增强他们有效使用该工具的能力。

相似文献

1
[Application of the Risk of Bias 2 Tool].[偏倚风险2工具的应用]
Hu Li Za Zhi. 2021 Apr;68(2):85-91. doi: 10.6224/JN.202104_68(2).11.
2
Frequency of use and adequacy of Cochrane risk of bias tool 2 in non-Cochrane systematic reviews published in 2020: Meta-research study.2020 年发表的非 Cochrane 系统评价中 Cochrane 偏倚风险工具 2 的使用频率和充分性:元研究。
Res Synth Methods. 2024 May;15(3):430-440. doi: 10.1002/jrsm.1695. Epub 2024 Jan 23.
3
Adequacy of risk of bias assessment in surgical vs non-surgical trials in Cochrane reviews: a methodological study.Cochrane 综述中手术与非手术试验的偏倚风险评估充分性:一项方法学研究。
BMC Med Res Methodol. 2020 Sep 29;20(1):240. doi: 10.1186/s12874-020-01123-7.
4
The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application.修订后的 Cochrane 随机对照试验偏倚风险工具(RoB 2)显示出较低的评分者间可靠性和应用方面的挑战。
J Clin Epidemiol. 2020 Oct;126:37-44. doi: 10.1016/j.jclinepi.2020.06.015. Epub 2020 Jun 18.
5
Risk of bias tools in systematic reviews of health interventions: an analysis of PROSPERO-registered protocols.健康干预措施系统评价中的偏倚风险工具:对 PROSPERO 注册方案的分析。
Syst Rev. 2019 Nov 15;8(1):280. doi: 10.1186/s13643-019-1172-8.
6
Cochrane risk of bias tool was used inadequately in the majority of non-Cochrane systematic reviews.Cochrane 偏倚风险工具在大多数非 Cochrane 系统评价中使用不当。
J Clin Epidemiol. 2020 Jul;123:114-119. doi: 10.1016/j.jclinepi.2020.03.019. Epub 2020 Apr 1.
7
Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials.随机序列生成偏倚风险评估:100 项试验系统评价研究。
Syst Rev. 2019 Jan 8;8(1):13. doi: 10.1186/s13643-018-0924-1.
8
Risk of bias judgments for random sequence generation in Cochrane systematic reviews were frequently not in line with Cochrane Handbook.Cochrane 系统评价中随机序列生成的偏倚风险判断常常与 Cochrane 手册不一致。
BMC Med Res Methodol. 2019 Aug 5;19(1):170. doi: 10.1186/s12874-019-0804-y.
9
The judgement of biases included in the category "other bias" in Cochrane systematic reviews of interventions: a systematic survey.Cochrane 系统评价干预措施中“其他偏倚”类别中偏倚的判断:系统调查。
BMC Med Res Methodol. 2019 Apr 11;19(1):77. doi: 10.1186/s12874-019-0718-8.
10
Risk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias Tool.噻唑烷二酮类药物和环氧化酶-2抑制剂心血管不良事件非随机研究系统评价中的偏倚风险:一种新的Cochrane偏倚风险工具的应用
PLoS Med. 2016 Apr 5;13(4):e1001987. doi: 10.1371/journal.pmed.1001987. eCollection 2016 Apr.

引用本文的文献

1
Safety and efficacy of side-by-side versus stent-in-stent stenting for malignant hilar biliary obstruction: a systematic review and meta-analysis.并排支架置入术与支架内支架置入术治疗恶性肝门部胆管梗阻的安全性和有效性:一项系统评价和荟萃分析。
Therap Adv Gastroenterol. 2024 Aug 27;17:17562848241271962. doi: 10.1177/17562848241271962. eCollection 2024.
2
Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.阿哌沙班与达肝素治疗癌症相关性静脉血栓栓塞症的疗效和安全性:系统评价和荟萃分析。
Medicina (Kaunas). 2023 Oct 20;59(10):1867. doi: 10.3390/medicina59101867.